This preprint is under consideration at a Nature Portfolio Journal. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Nature journals have partnered with Research Square to offer In Review, a journal-integrated preprint deposition service.
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
Teresa Lambe, Alexandra Spencer, Kelly Thomas, Stephen Thomas, Andrew White, Holly Humphries, Daniel Wright, Nazia Thakur, Carina Conceicao, Leonie Alden, Lauren Allen, Marilyn Aram, Kevin Bewley, Emily Brunt, Phillip Brown, Breeze Cavell, Rebecca Cobb, Susan Fotheringham, Ciaran Gilbride, Debbie Harris, Catherine Ho, Laura Hunter, Chelsea Kennard, Stephanie Leung, V Lucas, Didier Ngabo, Kathryn Ryan, Hannah Sharpe, Charlotte Sarfas, Laura Sibley, Gillian Slack, Marta Ulaszewska, Nadina wand, Nathan Wiblin, Fergus Gleeson, Dalan Bailey, Sally Sharpe, Sue Charlton, Francisco Salguero, Miles Carroll, Sarah Gilbert
Vaccines against SARS-CoV-2 are urgently required. Here we report detailed immune profiling after ChAdOx1 nCoV-19 (AZD1222) and subsequent challenge in two animal models of SARS-CoV-2 mediated disease. We demonstrate in rhesus macaques the lung pathology caused by SARS-CoV-2 mediated pneumonia is reduced by prior vaccination with ChAdOx1 nCoV-19 which induced neutralising antibody responses after a single intramuscular administration. In a second animal model, ferrets, ChAdOx1 nCoV-19 reduced both virus shedding and lung pathology. Antibody titers were boosted by a second dose. Data from these challenge models and the detailed immune profiling, support the continued clinical evaluation of ChAdOx1 nCoV-19.
Keywords
SARS-CoV-2, vaccines, immune profiling
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
This preprint is under consideration at a Nature Portfolio Journal. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Nature journals have partnered with Research Square to offer In Review, a journal-integrated preprint deposition service.
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
Teresa Lambe, Alexandra Spencer, Kelly Thomas, Stephen Thomas, Andrew White, Holly Humphries, Daniel Wright, Nazia Thakur, Carina Conceicao, Leonie Alden, Lauren Allen, Marilyn Aram, Kevin Bewley, Emily Brunt, Phillip Brown, Breeze Cavell, Rebecca Cobb, Susan Fotheringham, Ciaran Gilbride, Debbie Harris, Catherine Ho, Laura Hunter, Chelsea Kennard, Stephanie Leung, V Lucas, Didier Ngabo, Kathryn Ryan, Hannah Sharpe, Charlotte Sarfas, Laura Sibley, Gillian Slack, Marta Ulaszewska, Nadina wand, Nathan Wiblin, Fergus Gleeson, Dalan Bailey, Sally Sharpe, Sue Charlton, Francisco Salguero, Miles Carroll, Sarah Gilbert
Vaccines against SARS-CoV-2 are urgently required. Here we report detailed immune profiling after ChAdOx1 nCoV-19 (AZD1222) and subsequent challenge in two animal models of SARS-CoV-2 mediated disease. We demonstrate in rhesus macaques the lung pathology caused by SARS-CoV-2 mediated pneumonia is reduced by prior vaccination with ChAdOx1 nCoV-19 which induced neutralising antibody responses after a single intramuscular administration. In a second animal model, ferrets, ChAdOx1 nCoV-19 reduced both virus shedding and lung pathology. Antibody titers were boosted by a second dose. Data from these challenge models and the detailed immune profiling, support the continued clinical evaluation of ChAdOx1 nCoV-19.